MetaCap

Medpace Holdings Inc. (MEDP)

NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

610.54-23.44 (-3.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MEDP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$17.08B
EPS (TTM)
$18.01
52-week range
373.00 – 693.97
Day range
606.73 – 633.87
Volume / Avg
236.69K / 257.80K
Beta
—

52-week range

$373.00$693.97

MEDP stock today

Medpace (MEDP) closed at $610.54 on Nov 20, down 3.70% (-$23.44), versus the S&P 500's 3.70% decline. At this level, MEDP sits in the middle of its 52-week range of $373.00 to $693.97: 12.0% below the high, set on Oct 28, 2026 and 63.7% above the low. MEDP is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.2%.

At 33.9x trailing earnings, Medpace trades below the peer-group median of 74.7x. Its forward P/E of 30.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Medpace

Company profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Dr. August James Troendle M.D.
Headquarters
Cincinnati, OH
Employees
6,600
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Medpace generated $2.53 billion in revenue, up 20.0% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $451.1 million (+11.6% year over year), for a net margin of 17.8% versus a median of 15.9% in the prior 5 years. Operating margin was 21.1%.

Medpace annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B
Growth+19.97%+11.84%+29.17%+27.80%+23.38%
Net income$451.12M$404.39M$282.81M$245.37M$181.85M
EPS (diluted)$15.28$12.63$8.88$7.28$4.81

Analyst forecast

Forecast

Consensus (14 analysts)

none

Avg. price target

$651.31+6.68%

  • Strong buy 1
  • Buy 1
  • Hold 11
  • Sell 1
  • Strong sell 0

Target range

Low $370.00High $730.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 21, 2026
EPS actual vs est.
$3.86 vs $4.45
Surprise
-13.26%

MEDP news

All MEDP news

Medpace peers

Health Care sector
MEDP peer companies
CompanyPrice% ChgMarket capCompare
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs MEDP
ICLRICON plc186.71-1.92%$13.99Bvs MEDP
INCYIncyte Corp.114.63-1.07%$23.36Bvs MEDP
ABSIAbsci Corporation7.51-7.97%$1.30Bvs MEDP
OABIOmniAb Inc.4.66-7.36%$679.71Mvs MEDP
NRCNRC Health25.16+0.68%$533.93Mvs MEDP
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs MEDP
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs MEDP

Indexes, lists and sector

Medpace stock FAQ

What is Medpace's stock price today?

MEDP last traded at $610.54 as of Nov 20, 4:00 PM EST, down 3.70% on the day. Prices are delayed at least 15 minutes.

What is MEDP's P/E ratio?

MEDP trades at a trailing P/E ratio of 33.90 and a forward P/E of 30.74, compared with a median of 74.7 for its closest peers.

Who is Medpace's CEO?

Dr. August James Troendle M.D. is the chief executive officer of Medpace Holdings Inc., which has about 6,600 employees.

What is the MEDP 52-week high?

The 52-week high for MEDP is $693.97 and the 52-week low is $373.00. The stock is currently 12.0% below its high.

Compare MEDP